AGARWALEYE500.20

Dr. Agarwal's Health Care Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAKUMSADVENZYMESALIVUSAARTIPHARMAARTIDRUGSAPLLTDCORONAHCGMcap ₹15,846 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,711.02,080.12,206.7
Other Income46.044.437.5
Total Income1,757.02,124.52,244.1
Expenses
+ Cost of Materials Consumed1.20.91.0
+ Purchases of Stock-in-Trade173.7202.4217.7
+ Changes in Inventories-12.8-10.5-14.4
+ Employee Benefit Expense326.9403.8429.3
+ Finance Costs108.890.589.1
+ Depreciation & Amortisation230.7276.2291.6
+ Other Expenses765.7913.9960.9
Total Expenses1,594.21,877.21,975.3
EBITDA456.4569.6612.1
EBIT225.6293.3320.5
Profit
PBT before Exceptional Items162.9247.3268.9
+ Exceptional Items-3.01.31.3
Pretax Income159.9248.6270.2
+ Current Tax39.381.088.4
+ Deferred Tax10.3-0.5-3.3
Tax Expense49.580.585.1
Net Income110.3168.1185.1
+ Net Income — Continuing Ops110.3168.1185.1
+ Other Comprehensive Income-0.517.613.1
Total Comprehensive Income109.8185.7198.2
Net Income to Common83.5133.2148.4
Minority Interest26.935.036.7
Per Share
Basic EPS2.804.214.69
Diluted EPS2.784.184.65
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.517.613.1
+ Items NOT to be Reclassified to P&L-0.5-0.7-2.2
+ Tax on Items NOT to be Reclassified-0.1-0.2-0.6
+ Items to be Reclassified to P&L-0.118.1
+ Tax on Items to be Reclassified0.00.0-3.9
Comprehensive Income — Owners of Parent82.9150.8161.7
Comprehensive Income — Non-controlling Interests26.935.036.5
Per Share — as-filed variants
Basic EPS — Continuing Operations2.804.214.69
Diluted EPS — Continuing Operations2.784.184.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,548.91,887.32,002.4
Gross Margin %90.5390.7390.74
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)162.9247.3268.9
− Exceptional Items (reconciliation)-3.01.31.3
Net Income Adj (tax-effected)112.4167.2184.2
EPS Adj2.854.194.67
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.00
Paid Up Equity Capital31.631.731.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.